Searched for
NEUTROPENIA
Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...- Zydus to buy Assertio for $166.4 millionZydus is acquiring US-based Assertio Holdings for $166.40 million to bolster its specialty oncology presence in the US. The deal, structure...
- Zydus Lifesciences acquires US pharma firm Assertio for $166 millionIn a bold move that positions Zydus at the forefront of the U.S. specialty oncology market, the Indian drug manufacturer has secured a $166...
- Lupin gets USFDA nod for biosimilar drugLupin gets USFDA approval for Armlupeg, a biosimilar to Neulasta, to treat neutropenia in cancer patients. The drug will be manufactured at...
- Intas Pharma completes acquisition of UDENYCA biosimilar for $558 millionIntas Pharma finalized its acquisition of UDENYCA, a biosimilar to Neulasta, from Coherus Life Sciences for $558 million in December 2024. ...
- NPPA fixes retail price of 74 drug formulationsThe NPPA said it has also revised the ceiling price of 80 scheduled formulations (NLEM 2022) including the one to treat epilepsy and neutro...
- Aurobindo unit, Evive Biotech ink licensing pact to commercialise CIN treatment product in USNeutropenia is a common side-effect of chemotherapy and is a condition characterised by low levels of neutrophils, a type of white blood ce...
- Drug maker Lupin inks licensing pact with Axantia for PegfilgrastimPegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherap...
- Biocon, Mylan launch cancer drug in CanadaFulphila, co-developed by Biocon Biologics and Mylan, was the first biosimilar pegfilgrastim to be approved in the US and was launched in J...
- Biocon, Mylan launch cancer drug in AustraliaFulphila, co-developed by Biocon Biologics and Mylan, was the first biosimilar pegfilgrastim to be approved in the US and was launched in J...
- Biocon shares gain on updates on proposed biosimilars Trastuzumab and PegfilgrastimOn the BSE, 1.61 lakh shares were traded on the counter so far in the trade.
- USFDA accepts Mylan's BLA for proposed biosimilar PegfilgrastimThe proposed biosimilar Pegfilgrastim is one of the six biologic products co-developed by Mylan and Biocon for the global marketplace, the ...
- Biocon climbs 3% as USFDA accepts BLA for Mylan’s anti-cancer drug“This is the second BLA accepted for review by FDA as part of the Mylan and Biocon partnership within the past two months”, said Rajiv Mali...
- US FDA accepts Biocon-Mylan biosimilar application for proposed anti-cancer bio-similarBiocon said that the FDA's acceptance for review of this biosimilar is an outcome of the company’s strong R&D and manufacturing capabilitie...
- EMA accepts marketing application of Biocon, Mylan productMylan and Biocon, who co-developed the proposed biosimilar, received EMA's acceptance of the submission for review, Biocon said in a statem...
- Intas Pharma launches its first biosimilar product Accofil in EuropeThe product has recently been introduced under the brand Accofil and has already won two prestigious tenders, in Netherlands and the UK.
- Venus Remedies shares rally 10% on Mexico patent for PotentoxVenus Remedies shares rallied nearly 10% in morning trade, after the company received patent from Mexico for its novel antibiotic Potentox.
- Venus Remedies gets Mexico patent for PotentoxGranted by the Mexican Institute of Industrial Property, the patent protects the composition of Potentox, the company said.
- Biocon to develop neutropenia drug with US companyBiocon on Thursday said it will develop a drug for treatment of neutropenia, which refers to lowering of white blood cells count in the bod...
- Zenotech gets marketing nod for cancer drugZenotech Laboratories on Tuesday said it has received marketing approval for 'GM-CSF' and 'G-CSF', its generic versions for treating blood ...
Load More
